Two abstracts accepted for presentation One abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01 Another abstract on the use of Evaxion’s AI-Immunology™ ...
TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...
Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Safe Dividend Stocks for 2026. On March 12, Wells Fargo raised its ...
Stocktwits activity surged after the NCCN update, with message volumes jumping over 300% in 24 hours. ・Retail traders flagged ...